Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Generated: June 21, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021037

« Back to Dashboard

NDA 021037 describes MAGNEVIST, which is a drug marketed by Bayer Hlthcare and is included in two NDAs. It is available from two suppliers. Additional details are available on the MAGNEVIST profile page.

The generic ingredient in MAGNEVIST is gadopentetate dimeglumine. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the gadopentetate dimeglumine profile page.

Summary for 021037

Tradename:	MAGNEVIST
Applicant:	Bayer Hlthcare
Ingredient:	gadopentetate dimeglumine
Patents:	0
Formulation / Manufacturing:	see details

Suppliers and Packaging for NDA: 021037

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
MAGNEVIST	gadopentetate dimeglumine	INJECTABLE;INJECTION	021037	NDA AUTHORIZED GENERIC	Alvogen, Inc	47781-147	N	47781-147-20
MAGNEVIST	gadopentetate dimeglumine	INJECTABLE;INJECTION	021037	NDA AUTHORIZED GENERIC	Alvogen, Inc	47781-147	N	47781-147-22

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	INJECTABLE;INJECTION			Strength	469.01MG/ML
Approval Date:	Mar 10, 2000	TE:		RLD:	Yes

Expired US Patents for NDA 021037

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bayer Hlthcare	MAGNEVIST	gadopentetate dimeglumine	INJECTABLE;INJECTION	021037-001	Mar 10, 2000	➤ Sign Up	➤ Sign Up
Bayer Hlthcare	MAGNEVIST	gadopentetate dimeglumine	INJECTABLE;INJECTION	021037-001	Mar 10, 2000	➤ Sign Up	➤ Sign Up
Bayer Hlthcare	MAGNEVIST	gadopentetate dimeglumine	INJECTABLE;INJECTION	021037-001	Mar 10, 2000	➤ Sign Up	➤ Sign Up
Bayer Hlthcare	MAGNEVIST	gadopentetate dimeglumine	INJECTABLE;INJECTION	021037-001	Mar 10, 2000	➤ Sign Up	➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.